BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Ovarian cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for ovarian cancer: 389 (240 sponsors; 57 newly posted in the last 180 days, 25 stopped in the last 180 days; 29 new-entrant sponsors). Momentum score 11.6, rank 60 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 130, Phase 2 156, Phase 3 62, Phase 4 2, N/A 37.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 25 | P2 11, P3 8, NA 3, P1 3 | 2 | 2 |
| Merck Sharp & Dohme LLC MRK | 7 | P3 5, P2 1, P1 1 | 3 | 0 |
| Genmab GMAB | 6 | P3 5, P2 1 | 2 | 0 |
| Daiichi Sankyo | 6 | P3 3, P1 1, P2 2 | 1 | 1 |
| GlaxoSmithKline | 6 | P3 3, P4 1, P1 1, P2 1 | 2 | 1 |
| Incyte Corporation INCY | 4 | P3 2, P2 1, P1 1 | 1 | 1 |
| Hansoh BioMedical R&D Company | 3 | P3 2, P2 1 | 1 | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 3 | P3 2, P2 1 | 0 | 1 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 3 | P3 2, P2 1 | 1 | 1 |
| Tesaro, Inc. | 2 | P3 2 | 0 | 0 |
| Tolmar Inc. | 2 | P3 2 | 0 | 1 |
| AbbVie ABBV | 16 | P1 5, P2 6, NA 4, P3 1 | 3 | 3 |
| Eli Lilly and Company LLY | 9 | P1 6, P3 1, P2 2 | 1 | 3 |
| CanariaBio Inc. | 4 | P2 3, P3 1 | 0 | 3 |
| Verastem, Inc. VSTM | 4 | P2 3, P3 1 | 1 | 0 |
| EMD Serono Research & Development Institute, Inc. | 3 | P1 2, P3 1 | 0 | 2 |
| Imunon IMNN | 3 | P3 1, P2 2 | 0 | 0 |
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 3 | P1 1, P3 1, P2 1 | 0 | 1 |
| Qilu Pharmaceutical Co., Ltd. | 3 | P3 1, P2 2 | 2 | 1 |
| BeiGene | 2 | P3 1, P1 1 | 0 | 0 |
| Corcept Therapeutics CORT | 2 | P2 1, P3 1 | 0 | 0 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. new entrant | 2 | P2 1, P3 1 | 2 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Pfizer PFE | 2 | P2 1, P3 1 | 0 | 2 |
| Amgen AMGN | 1 | P3 1 | 0 | 0 |
New-entrant sponsors: CSPC Megalith Biopharmaceutical Co.,Ltd..
Recently stopped trials
- NCT06930755 Nerviano Medical Sciences - terminated: The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but a strategic decision driven by ch Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
- NCT07030907 Outpace Bio, Inc. - terminated: Business decision A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
- NCT05194735 Alaunos Therapeutics - terminated: Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
- NCT06756035 Context Therapeutics Inc. - terminated: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termi CT-95 in Advanced Cancers Associated With Mesothelin Expression
- NCT05617755 Arsenal Biosciences, Inc. - terminated: Active patients have been rolled over to a separate LTFU study. AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
- NCT06171789 Genmab - terminated: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation PRO1107 in Patients With Advanced Solid Tumors
- NCT05613088 Bristol-Myers Squibb - terminated: Business objectives have changed. A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade
- NCT04729387 Novartis Pharmaceuticals - terminated: Sponsor Decision Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutati
- NCT05601752 USWM CT, LLC - terminated: Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURP
- NCT05124743 Alaunos Therapeutics - terminated: Screening moved into TCR001-201 under Amendment 4 (IRB approved 20 Jan 2023; implemented February 2023). Previously enrolled participants co HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumor
- NCT06714617 SystImmune Inc. - terminated: The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the i Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
- NCT04614051 Pharmicell Co., Ltd. - terminated: Difficulties in patient recruitment. A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian Cancer
- NCT07181720 Chongqing Precision Biotech Co., Ltd - suspended: Sponsor stopped the study. CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
- NCT06206746 May Health - terminated: Business decision by sponsor to terminate the study The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
- NCT06315491 Cybrexa Therapeutics - terminated: Limited clinical activity A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2/P3 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | NCT05924776 Plasmodium Immunotherapy for Advanced Ovarian Cancer | Advanced Ovarian Cancer | not yet recruiting | 30 |
| 2026-12 est. | P3 | Genelux Corporation GNLX | NCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primar | recruiting | 186 |
| 2026-12 est. | P1/P2 | 858 Therapeutics, Inc. | NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovar | recruiting | 120 |
| 2026-12 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | Ovarian Cancer | recruiting | 150 |
| 2026-12-01 est. | P2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | NCT05128825 A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | recruiting | 310 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-26 est. | P3 | CanariaBio Inc. | NCT04498117 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Fal | active not recruiting | 615 |
| 2026-12-28 est. | P2 | GlaxoSmithKline | NCT04641247 A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Ovarian Neoplasms; Breast Neoplasms | recruiting | 37 |
| 2026-12-30 est. | P2 | CanariaBio Inc. | NCT05335993 A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | Recurrent Ovarian Cancer; Recurrent Epithelial Cancer of Ovary; Recurrent Epithelial Ovarian Cancer; | active not recruiting | 10 |
| 2026-12-30 est. | P3 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers | not yet recruiting | 430 |
| 2026-12-30 est. | P1/P2 | Astellas Pharma Global Development, Inc. | NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metasta | active not recruiting | 240 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
| 2026-12-31 est. | P3 | Pfizer PFE | NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors | active not recruiting | 77 |
| 2026-12-31 est. | P2 | Shanghai Jiaolian Drug Research and Development Co., Ltd | NCT06434610 A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. | Platinum-resistant Recurrent Ovarian Cancer | recruiting | 90 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2026-12-31 est. | P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT06730581 Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | Gastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer; Bile Duct Cancer | not yet recruiting | 100 |
| 2026-12-31 est. | P2 | Shanghai Henlius Biotech | NCT06769152 A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors | Cervical Cancer; Ovarian Cancer | recruiting | 190 |
| 2026-12-31 est. | P1/P2 | Evopoint Biosciences Inc. | NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | Advanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancers | recruiting | 350 |
| 2027-01 est. | P1/P2 | BicycleTx Limited | NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negative | active not recruiting | 329 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-02 est. | P1/P2 | Day One Biopharmaceuticals, Inc. | NCT05377996 A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Triple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Can | recruiting | 360 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Fol | Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive | active not recruiting | 108 |
| 2027-02-17 est. | P1/P2 | Beijing Biotech | NCT07480954 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) | Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma; Recurrent or Refr | recruiting | 36 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | AbbVie ABBV | NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Canc | High Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer | active not recruiting | 125 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-09-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07124793 A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors | EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | not yet recruiting | 60 |
| 2026-08-30 | P2 | OncoC4, Inc. | NCT05446298 ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian T | active not recruiting | 58 |
| 2026-08-18 | P3 | Genmab GMAB | NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Platinum-resistant Ovarian Cancer | active not recruiting | 584 |
| 2026-08-11 | P2 | EMD Serono Research & Development Institute, Inc. | NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | Ovarian Cancer | completed | 63 |
| 2026-08 est. | P2 | Clinique Ovo | NCT06997900 Menopur And Rekovelle Combination Study Version 2.0 | IVF; Controlled Ovarian Simulation; Fertility Disorders | recruiting | 200 |
| 2026-08 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervic | not yet recruiting | 120 |
| 2026-08 est. | P1/P2 | AtlasMedx, Incorporated | NCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Advanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Pro | recruiting | 122 |
| 2026-07-27 est. | P3 | AstraZeneca AZN | NCT04884360 D9319C00001- 1L OC Mono Global RCT | Ovarian Cancer | active not recruiting | 366 |
| 2026-07-01 est. | P1/P2 | Scancell Ltd SCNLD | NCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer | Triple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamous | recruiting | 168 |
| 2026-07 est. | P2 | AbbVie ABBV | NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritone | Advanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancers | recruiting | 110 |
| 2026-06-15 est. | P2/P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06211023 A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | Ovarian Cancer | unknown | 520 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06 est. | P1/P2 | Volastra Therapeutics, Inc. | NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer | recruiting | 200 |
| 2026-05-31 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | Ovarian Cancer | recruiting | 440 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "ovarian cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.